At week 104 , canagliflozin 100 and 300mg were associated with reductions in HbA1c versus placebo ( -0.32 and -0.43 % vs 0.17 % , respectively ; overall mean baseline , 7.7 % ) and more patients achieved HbA1c < 7.0 % with canagliflozin 100 and 300mg than with placebo ( 35.8 and 41.9 % vs 20.3 % , respectively ) .